Ballentine Partners’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.35M | Sell |
6,119
-633
| -9% | -$175K | 0.02% | 306 |
|
|
2026
Q1 | $1.99M | Buy |
6,752
+20
| +0.3% | +$5.94K | 0.03% | 203 |
|
|
2025
Q4 | $1.84M | Buy |
6,732
+267
| +4% | +$72.6K | 0.03% | 203 |
|
|
2025
Q3 | $1.75M | Buy |
6,465
+18
| +0.3% | +$4.9K | 0.02% | 218 |
|
|
2025
Q2 | $1.78M | Buy |
6,447
+619
| +11% | +$168K | 0.03% | 214 |
|
|
2025
Q1 | $1.55M | Buy |
5,828
+45
| +0.8% | +$11.1K | 0.03% | 218 |
|
|
2024
Q4 | $1.34M | Buy |
5,783
+367
| +7% | +$84.4K | 0.02% | 236 |
|
|
2024
Q3 | $1.2M | Buy |
5,416
+351
| +7% | +$72.6K | 0.02% | 249 |
|
|
2024
Q2 | $996K | Sell |
5,065
-189
| -4% | -$39K | 0.02% | 262 |
|
|
2024
Q1 | $1.13M | Buy |
5,254
+60
| +1% | +$12.6K | 0.02% | 219 |
|
|
2023
Q4 | $1.09M | Buy |
5,194
+121
| +2% | +$25.8K | 0.02% | 219 |
|
|
2023
Q3 | $1.02M | Buy |
5,073
+159
| +3% | +$31.6K | 0.02% | 199 |
|
|
2023
Q2 | $911K | Sell |
4,914
-23
| -0.5% | -$4.25K | 0.02% | 208 |
|
|
2023
Q1 | $946K | Buy |
4,937
+741
| +18% | +$134K | 0.02% | 199 |
|
|
2022
Q4 | $706K | Buy |
4,196
+162
| +4% | +$28.2K | 0.02% | 227 |
|
|
2022
Q3 | $714K | Buy |
4,034
+521
| +15% | +$103K | 0.02% | 192 |
|
|
2022
Q2 | $719K | Buy |
3,513
+176
| +5% | +$37.3K | 0.03% | 188 |
|
|
2022
Q1 | $793K | Buy |
3,337
+143
| +4% | +$33.6K | 0.02% | 198 |
|
|
2021
Q4 | $730K | Hold |
3,194
| – | – | 0.02% | 218 |
|
|
2021
Q3 | $617K | Sell |
3,194
-29
| -0.9% | -$5.88K | 0.02% | 210 |
|
|
2021
Q2 | $686K | Buy |
3,223
+14
| +0.4% | +$2.96K | 0.02% | 194 |
|
|
2021
Q1 | $655K | Buy |
3,209
+114
| +4% | +$22.5K | 0.02% | 192 |
|
|
2020
Q4 | $563K | Sell |
3,095
-564
| -15% | -$95.9K | 0.02% | 204 |
|
|
2020
Q3 | $612K | Sell |
3,659
-3,127
| -46% | -$527K | 0.03% | 186 |
|
|
2020
Q2 | $1.1M | Buy |
6,786
+4,091
| +152% | +$733K | 0.05% | 132 |
|
|
2020
Q1 | $466K | Buy |
2,695
+987
| +58% | +$196K | 0.03% | 194 |
|
|
2019
Q4 | $343K | Buy |
1,708
+86
| +5% | +$17.6K | 0.02% | 283 |
|
|
2019
Q3 | $343K | Buy |
1,622
+12
| +0.7% | +$2.51K | 0.02% | 263 |
|
|
2019
Q2 | $313K | Buy |
+1,610
| New | +$297K | 0.02% | 282 |
|
|
2019
Q1 | – | Sell |
-1,169
| Closed | -$220K | – | 335 |
|
|
2018
Q4 | $220K | Buy |
+1,169
| New | +$216K | 0.01% | 290 |
|
Other funds holding CME
Ballentine Partners's CME Position: Q2 2026 in Review
Ballentine Partners reduced its CME Group (CME) stake by 9.4% in Q2 2026, selling an estimated $175K and leaving 6,119 shares worth $1.35M. The position accounts for 0.02% of the portfolio, ranked #306.
Ballentine Partners first reported a position in CME in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.99M in Q1 2026. 1,703 funds tracked by Wall St. Rank hold CME as of Q2 2026.
- Ballentine Partners held 6,119 shares of CME Group worth $1.35M as of Q2 2026.
- Ballentine Partners sold 633 CME Group shares in Q2 2026, an estimated $175K.
- CME Group made up 0.02% of Ballentine Partners's portfolio in Q2 2026, its #306 holding.
- Ballentine Partners first reported a position in CME Group in Q4 2018 and has held it in 30 quarters since.
- Ballentine Partners's CME Group position peaked at $1.99M in Q1 2026.
- 1,703 funds tracked by Wall St. Rank held CME Group as of Q2 2026.
Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.